Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Lancet Gastroenterol Hepatol

Retrieve available abstracts of 91 articles:
HTML format



Single Articles


    December 2021
  1. AHMED W, Lukin DJ
    A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:973-975.
    PubMed    


    November 2021
  2. LASA JS, Olivera PA, Danese S, Peyrin-Biroulet L, et al
    Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00377.
    PubMed     Abstract available


  3. MA C, Choi MY
    Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00432.
    PubMed    


  4. TAKENAKA K, Fujii T, Kawamoto A, Suzuki K, et al
    Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00372.
    PubMed     Abstract available


  5. PEYRIN-BIROULET L, Hart A, Bossuyt P, Long M, et al
    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00298.
    PubMed     Abstract available


  6. DANESE S, Colombel JF, Lukas M, Gisbert JP, et al
    Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00294.
    PubMed     Abstract available


  7. VERMEIRE S, Lakatos PL, Ritter T, Hanauer S, et al
    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00295.
    PubMed     Abstract available


  8. RUBIN DT, Dotan I, DuVall A, Bouhnik Y, et al
    Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00338.
    PubMed     Abstract available


  9. AGRAWAL M, Verstockt B
    Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00369.
    PubMed    


  10. MOURAD FH, Hashash JG
    Inflammatory bowel disease in Lebanon: a plea for help.
    Lancet Gastroenterol Hepatol. 2021 Nov 11. pii: S2468-1253(21)00390.
    PubMed    


  11. ASWANI-OMPRAKASH T, Sharma V, Bishu S, Balasubramaniam M, et al
    Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance.
    Lancet Gastroenterol Hepatol. 2021;6:884-885.
    PubMed    


    October 2021
  12. SELIM R, Wellens J, Marlow L, Satsangi JJ, et al
    SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.
    Lancet Gastroenterol Hepatol. 2021 Oct 13. pii: S2468-1253(21)00347.
    PubMed    


  13. ALEXANDER JL, Selinger CP, Powell N
    Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Oct 12. pii: S2468-1253(21)00374.
    PubMed    


  14. SHEN B, Kochhar GS, Kariv R, Liu X, et al
    Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2021;6:826-849.
    PubMed     Abstract available


  15. HANAUER S, Liedert B, Balser S, Brockstedt E, et al
    Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2021;6:816-825.
    PubMed     Abstract available


    September 2021
  16. SHEN B, Bortlik M, Bruining DH, Coelho-Prabhu N, et al
    Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:691-692.
    PubMed    


  17. SYAL G, Fleshner PR, Melmed GY
    Endoscopic evaluation after surgery in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:690-691.
    PubMed    


  18. KOBAYASHI T
    Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:688.
    PubMed    


  19. TAN M, Ng V, Lim CT, Leow WQ, et al
    Stringent criteria for withdrawal of biologics in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021;6:687-688.
    PubMed    


    August 2021
  20. FIORINO G, Allocca M, Danese S
    Adalimumab biosimilar in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Aug 10. pii: S2468-1253(21)00266.
    PubMed    


  21. GEYL S, Guillo L, Laurent V, D'Amico F, et al
    Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2021;6:659-667.
    PubMed     Abstract available


    July 2021
  22. SASSON AN, Ingram RJM, Zhang Z, Taylor LM, et al
    The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Jul 13. pii: S2468-1253(21)00097.
    PubMed     Abstract available


  23. GARRIDO HMG, Grobusch MP, D'Haens GRAM, Goorhuis A, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:523.
    PubMed    


  24. ALEXANDER JL, Kennedy NA, Lees CW, Ahmad T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:523-524.
    PubMed    


  25. DIN S, Gaya DR, Arnott IDR
    COVID-19: Colorectal cancer endoscopic surveillance in IBD.
    Lancet Gastroenterol Hepatol. 2021;6:526-527.
    PubMed    


    June 2021
  26. CROFT NM, Faubion WA Jr, Kugathasan S, Kierkus J, et al
    Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Jun 18. pii: S2468-1253(21)00142.
    PubMed     Abstract available


    May 2021
  27. ALEXANDER JL, Powell N
    SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?
    Lancet Gastroenterol Hepatol. 2021 May 25. pii: S2468-1253(21)00184.
    PubMed    


  28. DANESE S, Parigi TL, Peyrin-Biroulet L, Ghosh S, et al
    Defining difficult-to-treat inflammatory bowel disease: why and how.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00141.
    PubMed    


  29. ALSOUD D, Verstockt B, Fiocchi C, Vermeire S, et al
    Breaking the therapeutic ceiling in drug development in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00065.
    PubMed     Abstract available


  30. SEGAL JP, Kumar A, Raine T, Lamb CA, et al
    The impact of SARS-CoV-2 variants on IBD management.
    Lancet Gastroenterol Hepatol. 2021;6:343-344.
    PubMed    


    April 2021
  31. UNGAR B
    Infliximab discontinuation in patients with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00103.
    PubMed    


  32. KOBAYASHI T, Motoya S, Nakamura S, Yamamoto T, et al
    Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00062.
    PubMed     Abstract available


  33. SHEN B, Kochhar GS, Navaneethan U, Cross RK, et al
    Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.
    Lancet Gastroenterol Hepatol. 2021 Apr 16. pii: S2468-1253(20)30394.
    PubMed     Abstract available


    March 2021
  34. BARBERIO B, Zamani M, Black CJ, Savarino EV, et al
    Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00014.
    PubMed     Abstract available


  35. KEEFER L
    What can we do to tackle anxiety and depression in patients with inflammatory bowel disease?
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00066.
    PubMed    


  36. SEGAL JP, Kayal M, Kochhar G, Dubinsky MC, et al
    The ileoanal pouch: the next frontier in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:164-165.
    PubMed    


  37. JENA A, Jha DK, Sharma V
    Distinguishing intestinal tuberculosis from Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:159.
    PubMed    


  38. BANERJEE R, Pal P
    Distinguishing intestinal tuberculosis from Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:159-160.
    PubMed    


    February 2021
  39. SEBASTIAN S, Walker GJ, Kennedy NA, Conley TE, et al
    Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00016.
    PubMed     Abstract available


  40. SHEN B
    Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00009.
    PubMed    


  41. VERMA AM, Patel A, Subramanian S, Smith PJ, et al
    From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Lancet Gastroenterol Hepatol. 2021;6:88-89.
    PubMed    


    January 2021
  42. ALEXANDER JL, Moran GW, Gaya DR, Raine T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
    Lancet Gastroenterol Hepatol. 2021 Jan 25. pii: S2468-1253(21)00024.
    PubMed     Abstract available


    December 2020
  43. NG SC, Mak JWY, Pal P, Banerjee R, et al
    Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1089-1100.
    PubMed     Abstract available


  44. BANERJEE R, Pal P, Mak JWY, Ng SC, et al
    Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1076-1088.
    PubMed     Abstract available


  45. STRID H
    Prevalence of IBS-type symptoms in IBD.
    Lancet Gastroenterol Hepatol. 2020;5:1029-1031.
    PubMed    


    November 2020
  46. AZIZ I, Simren M
    The overlap between irritable bowel syndrome and organic gastrointestinal diseases.
    Lancet Gastroenterol Hepatol. 2020 Nov 12. pii: S2468-1253(20)30212.
    PubMed     Abstract available


    October 2020
  47. MA C, Panaccione R
    Harnessing localised delivery of gut-selective therapy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30292.
    PubMed    


  48. ATREYA R, Peyrin-Biroulet L, Klymenko A, Augustyn M, et al
    Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30301.
    PubMed     Abstract available


  49. AREBI N
    Surgery versus infliximab for Crohn's disease: should there be a change in clinical practice?
    Lancet Gastroenterol Hepatol. 2020;5:877-878.
    PubMed    


  50. BRENNER EJ, Ungaro RC, Colombel JF, Kappelman MD, et al
    IBD in the COVID-19 era: the value of international collaboration.
    Lancet Gastroenterol Hepatol. 2020;5:887-888.
    PubMed    


  51. STEVENS TW, Haasnoot ML, D'Haens GR, Buskens CJ, et al
    Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
    Lancet Gastroenterol Hepatol. 2020;5:900-907.
    PubMed     Abstract available


  52. FAIRBRASS KM, Costantino SJ, Gracie DJ, Ford AC, et al
    Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2020 Oct 1. pii: S2468-1253(20)30300.
    PubMed     Abstract available


    September 2020
  53. KUMAR A, Quraishi MN, Segal JP, Raine T, et al
    COVID-19 vaccinations in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2020 Sep 21. pii: S2468-1253(20)30295.
    PubMed    


  54. RAINE T, Verstockt B, De Cruz P
    Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?
    Lancet Gastroenterol Hepatol. 2020;5:794-796.
    PubMed    


  55. SLEUTJES JAM, de Vries AC, van der Woude CJ
    Ozanimod in Crohn's disease: a promising new player.
    Lancet Gastroenterol Hepatol. 2020;5:791-792.
    PubMed    


  56. FEAGAN BG, Sandborn WJ, Danese S, Wolf DC, et al
    Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Lancet Gastroenterol Hepatol. 2020;5:819-828.
    PubMed     Abstract available


    August 2020
  57. NGUYEN LH, Ortqvist AK, Cao Y, Simon TG, et al
    Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden.
    Lancet Gastroenterol Hepatol. 2020 Aug 17. pii: S2468-1253(20)30267.
    PubMed     Abstract available


  58. SOKOL H
    Antibiotics: a trigger for inflammatory bowel disease?
    Lancet Gastroenterol Hepatol. 2020 Aug 17. pii: S2468-1253(20)30208.
    PubMed    


  59. RUDDY J, Taft T, Siau K, Bollipo S, et al
    Emotional state should not be used to differentiate IBD from IBS.
    Lancet Gastroenterol Hepatol. 2020;5:723.
    PubMed    


  60. IACUCCI M, Cannatelli R, Labarile N, Ghosh S, et al
    Emotional state should not be used to differentiate IBD from IBS - Authors' reply.
    Lancet Gastroenterol Hepatol. 2020;5:723-724.
    PubMed    


    July 2020
  61. DING NS, An P, Dong W, Ding Y, et al
    Prevention of COVID-19 in patients with IBD - Authors' reply.
    Lancet Gastroenterol Hepatol. 2020;5:640-641.
    PubMed    


    June 2020
  62. ORR WC, Fass R, Sundaram SS, Scheimann AO, et al
    The effect of sleep on gastrointestinal functioning in common digestive diseases.
    Lancet Gastroenterol Hepatol. 2020;5:616-624.
    PubMed     Abstract available


    May 2020
  63. SEGAL JP, Quraishi MN, Bhala N, Brookes MJ, et al
    Prevention of COVID-19 in patients with IBD.
    Lancet Gastroenterol Hepatol. 2020 May 19. pii: S2468-1253(20)30153.
    PubMed    


  64. FIORINO G, Peyrin-Biroulet L, Danese S
    Protecting patients with IBD during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2020 May 19. pii: S2468-1253(20)30152.
    PubMed    


  65. CHEN Y, Hu S, Wu H, Farraye FA, et al
    Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2020 May 13. pii: S2468-1253(20)30131.
    PubMed    


  66. D'AMICO F, Rahier JF, Leone S, Peyrin-Biroulet L, et al
    Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey.
    Lancet Gastroenterol Hepatol. 2020 May 13. pii: S2468-1253(20)30151.
    PubMed    


  67. HAN J, Zhu L, Wang Y, Zeng Z, et al
    Resumption of daily services in a gastroenterology department in Guangzhou, China, in the wake of COVID-19.
    Lancet Gastroenterol Hepatol. 2020 May 4. pii: S2468-1253(20)30133.
    PubMed    


  68. SELINGER CP
    Biologicals are the main contributor to cost of care for IBD: a European perspective.
    Lancet Gastroenterol Hepatol. 2020;5:421-422.
    PubMed    


  69. LOUGHMAN A, Staudacher HM
    Treating the individual with diet: is gut microbiome testing the answer?
    Lancet Gastroenterol Hepatol. 2020;5:437.
    PubMed    


    April 2020
  70. AN P, Ji M, Ren H, Su J, et al
    Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China.
    Lancet Gastroenterol Hepatol. 2020 Apr 17. pii: S2468-1253(20)30121.
    PubMed    


  71. IACUCCI M, Cannatelli R, Labarile N, Mao R, et al
    Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period.
    Lancet Gastroenterol Hepatol. 2020 Apr 16. pii: S2468-1253(20)30119.
    PubMed     Abstract available


  72. MUSHTAQ A, Kazi F
    Switching to biosimilars: boon or bust?
    Lancet Gastroenterol Hepatol. 2020;5:341-342.
    PubMed    


    March 2020
  73. ZINGONE F, Savarino EV
    Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.
    Lancet Gastroenterol Hepatol. 2020 Mar 25. pii: S2468-1253(20)30085.
    PubMed    


  74. SHIVAJI UN, Nardone OM, Cannatelli R, Smith SC, et al
    Small molecule oral targeted therapies in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020 Mar 11. pii: S2468-1253(19)30414.
    PubMed     Abstract available


  75. MAO R, Liang J, Shen J, Ghosh S, et al
    Implications of COVID-19 for patients with pre-existing digestive diseases.
    Lancet Gastroenterol Hepatol. 2020 Mar 11. pii: S2468-1253(20)30076.
    PubMed    


  76. OLESEN SW, Panchal P, Chen J, Budree S, et al
    Global disparities in faecal microbiota transplantation research.
    Lancet Gastroenterol Hepatol. 2020;5:241.
    PubMed    


    February 2020
  77. BURISCH J, Vardi H, Schwartz D, Friger M, et al
    Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30012.
    PubMed     Abstract available


  78. HOU JK
    Colorectal cancer in Crohn's disease: closing the gap.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30046.
    PubMed    


  79. OLEN O, Erichsen R, Sachs MC, Pedersen L, et al
    Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30005.
    PubMed     Abstract available


  80. HASTINGS B
    Successful control of ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020;5:116.
    PubMed    


    January 2020
  81. SHEN B, Kochhar G, Navaneethan U, Farraye FA, et al
    Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group.
    Lancet Gastroenterol Hepatol. 2020 Jan 16. pii: S2468-1253(19)30366.
    PubMed     Abstract available


  82. CHAPMAN TP, Gomes CF, Louis E, Colombel JF, et al
    De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2020;5:63-79.
    PubMed     Abstract available


  83. NOOR NM, Verstockt B, Parkes M, Lee JC, et al
    Personalised medicine in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2020;5:80-92.
    PubMed     Abstract available


    December 2019
  84. WALJEE AK, Higgins PDR, Jensen CB, Villumsen M, et al
    Anti-tumour necrosis factor-alpha therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
    Lancet Gastroenterol Hepatol. 2019 Dec 10. pii: S2468-1253(19)30362.
    PubMed     Abstract available


  85. IACUCCI M, Cannatelli R, Tontini GE, Panaccione R, et al
    Improving the quality of surveillance colonoscopy in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019;4:971-983.
    PubMed     Abstract available


  86. O'KEEFE SJ
    The association between dietary fibre deficiency and high-income lifestyle-associated diseases: Burkitt's hypothesis revisited.
    Lancet Gastroenterol Hepatol. 2019;4:984-996.
    PubMed     Abstract available


    November 2019
  87. D'HAENS G, Pinzani M
    Intestinal and hepatic fibrosis: how are they similar?
    Lancet Gastroenterol Hepatol. 2019;4:820-822.
    PubMed    


    October 2019
  88. JAIRATH V, Feagan BG
    Global burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019 Oct 21. pii: S2468-1253(19)30358.
    PubMed    



  89. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet Gastroenterol Hepatol. 2019 Oct 21. pii: S2468-1253(19)30333.
    PubMed     Abstract available


    February 2019
  90. TAYLOR SA, Halligan S, Bhatnagar G, Gupta A, et al
    Diagnostic accuracy of MRE and ultrasound for Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2019;4:96.
    PubMed    


  91. NOVAK K, Maaser C, Wilkens R, Maconi G, et al
    Diagnostic accuracy of MRE and ultrasound for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2019;4:95-96.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: